Anders Boutrup Funch

Mr. Anders Boutrup Funch

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
AGAnne-Sofie Østergaard Gadsbøll
Anne-Sofie Østergaard Gadsbøll
MJMia H. Jee
Mia H. Jee
AFAnders Boutrup Funch
Anders Boutrup Funch
MAMaria Alhede
Maria Alhede
VMVeronika Mraz
Veronika Mraz
CBCharlotte M. Bonefeld
Charlotte M. Bonefeld

25 April 2025 in Cells
Verified
Journal Article
Open access
PDF file
LSLi-li Shi
Li-li Shi
PXPeng Xiong
Peng Xiong
MYMinglin Yang
Minglin Yang
OAOzge Ardicli
Ozge Ardicli
SSStephan Raphael Schneider
Stephan Raphael Schneider
MAMubeccel Akdis
Mubeccel Akdis
Immunoglobulin G4 (IgG4), a unique subclass of IgG antibodies, plays diverse roles in human health and disease. Its distinct features, such as Fab-arm exchange and specific mutations, confer reduced effector functions compared to other IgG subclasses. In health, IgG4 responses contribute to immune tolerance, particularly in the context of allergen-specific immunotherapy (AIT), where they can mediate tolerance to environmental antigens, inhibit IgE-dependent mast cell degranulation, and compete with IgE for allergen binding. This helps in attenuating allergic symptoms and is associated with increased levels of allergen-specific IgG4. However, in disease scenarios, the role of IgG4 is complex. IgG4 lacks complement fixation and, thus, shows a reduced ability to activate immune effector pathways, it was initially thought to be protective against autoimmune diseases. However, emerging evidence suggests that it can contribute to pathology. For instance, IgG4 autoantibodies against specific antigens can aggravate conditions in certain autoimmune disorders. In some cancers, it may play a role in immune evasion, with higher levels correlating with poor patient survival, albeit in others, its exact function remains elusive. Overall, understanding the precise role of IgG4 in various physiological and pathological conditions is crucial for developing targeted therapeutic strategies and improving patient outcomes.

28 September 2024 in Contact Dermatitis
Verified
Journal Article
Open access
CLChristoffer Kursawe Larsen
Christoffer Kursawe Larsen
AFAnders Boutrup Funch
Anders Boutrup Funch
HVHelen Vaher
Helen Vaher
RLRebecca Kitt Davidson Lohmann
Rebecca Kitt Davidson Lohmann
MJMia Hamilton Jee
Mia Hamilton Jee
JJJeanne D. Johansen
Jeanne D. Johansen
Background: Rubber accelerators are used in the vulcanization of rubber. However, rubber accelerators for example tetraethylthiuram disulfide (TETD) and zinc diethyldithiocarbamate (ZDEC) may cause contact allergy. Concomitant reactions between ZDEC and TETD have been observed in patients which could be explained by co‐ or cross‐reactivity.Objectives: To investigate cross‐reactivity between TETD and ZDEC and vice versa.Methods: Groups of mice were sensitized with TETD or ZDEC based on reported EC3‐values. Proliferation of lymphocytes were measured on day 5. To test cross‐reactivity, mice were sensitized and challenged 3 weeks later with TETD or ZDEC. The inflammatory response was measured by changes in ear thickness and the proliferative response in CD4+ and CD8+ T cells in the submandibular and cervical draining lymph nodes.Results: Sensitization of mice with doses of ZDEC 3%, TETD 5.6% or TETD 16.2% induced significant increased ear thickness and proliferation of CD4+ and CD8+ T cells. Challenge with ZDEC or TETD in these groups induced significant increased ear thickness. Challenge with ZDEC in mice sensitized to TETD 5.6% or TETD 16.2% induced significant increased proliferation of CD4+ and CD8+ T cells.Conclusions: We show cross‐reactivity between TETD and ZDEC. Patients sensitized to TETD or ZDEC should avoid exposure to both ZDEC and TETD.

4 January 2024 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
AFAnders Boutrup Funch
Anders Boutrup Funch
MAMagnus Glindvad Ahlström
Magnus Glindvad Ahlström
JJJeanne D Johansen
Jeanne D Johansen
GGGeisler Geisler
Geisler Geisler
CBCharlotte M Bonefeld
Charlotte M Bonefeld
Dear Editor, Allergic contact dermatitis (ACD) is a highly prevalent inflammatory skin disease affecting approximately 15% of the European population.1 ACD is classified as a delayed-type hypersensitivity reaction mediated by ­allergen-specific memory T cells. The delayed nature of ACD is typically observed following patch testing of allergic patients where the patches are applied on the back of the patient. Using the back is both effective and practical due to the large surface area and because the skin of the back has typically not previously been exposed to contact allergens.2 If the patient is allergic to the given allergen in a patch, a local eczematous skin lesion will typically appear within 2–7 days after the patch has been applied.2,3 However, some patients develop dermatitis within a few hours after re-exposure of ACD healed skin to the contact allergen.4,5 This form of rapid-onset ACD was first observed in animal experiments in 1963 and referred to as ‘rapid re-test reactions’.6 Subsequently, allergen-specific CD8+ skin-resident memory T (TRM) cells have been shown to drive the rapid-onset ACD reactions as they persist over time locally within ACD healed skin.5,7

11 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AFAnders Boutrup Funch
Anders Boutrup Funch
GGGeisler Geisler
Geisler Geisler
CBCharlotte Menné Bonefeld
Charlotte Menné Bonefeld
Allergic contact dermatitis (ACD) is a common inflammatory skin disease induced by exposure of the skin to contact allergens. Classically, ACD is defined as a delayed-type (type IV) hypersensitivity reaction mediated by allergen-specific T cells, with symptoms peaking 48–72 h after exposure to the contact allergen. This delayed response to the contact allergen is seen during patch testing, where allergen-naïve, unaffected skin of allergic individuals is exposed to the contact allergen. However, in daily life and in certain occupational settings, allergic individuals often experience rapid flare-ups/exacerbations with intensely itching erythema, oedema, and often vesicles within hours after re-exposure to the specific contact allergen. These rapid flare-ups only develop at skin sites previously exposed to the contact allergen. Thus, it is important to distinguish between the rapid-onset reaction typically experienced by the allergic individual and the delayed-type reaction typically seen after patch testing. This review summarizes current insights into the immunopathology of rapid- versus delayed-type ACD reactions and outlines potential therapeutic opportunities, as well as their current limitations, against rapid-onset ACD, including modulation of cytokine signaling, T cell survival, checkpoint pathways, and redox balance.

23 May 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
LGLouise Goksøyr
Louise Goksøyr
AFAnders Boutrup Funch
Anders Boutrup Funch
AOAnna K. Okholm
Anna K. Okholm
TTThor Grundtvig Theander
Thor Grundtvig Theander
WJWillem Adriaan de Jongh
Willem Adriaan de Jongh
ABAdam F. Sander Bertelsen
Adam F. Sander Bertelsen
Hypersensitivity to a contact allergen is one of the most abundant forms of inflammatory skin disease. Today, more than 20% of the general population are sensitized to one or more contact allergens, making this disease an important healthcare issue, as re-exposure to the allergen can initiate the clinical disease termed allergic contact dermatitis (ACD). The current standard treatment using corticosteroids is effective, but it has side effects when used for longer periods. Therefore, there is a need for new alternative therapies for severe ACD. In this study, we used the versatile Tag/Catcher AP205 capsid virus-like particle (cVLP) vaccine platform to develop an IL-1β-targeted vaccine and to assess the immunogenicity and in vivo efficacy of the vaccine in a translational mouse model of ACD. We show that vaccination with cVLPs displaying full-length murine IL-1β elicits high titers of neutralizing antibodies, leading to a significant reduction in local IL-1β levels as well as clinical symptoms induced by treatment with 1-Fluoro-2,4-dinitrobenzene (DNFB). Moreover, we show that a single amino acid mutation in muIL-1β reduces the biological activity while maintaining the ability to induce neutralizing antibodies. Collectively, the data suggest that a cVLP-based vaccine displaying full-length IL-1β represents a promising vaccine candidate for use as an alternative treatment modality against severe ACD.